Companies in #Glioblastoma

Clinical-stage Chinese biotech developing CAR-T cell therapies for solid tumors and hematological malignancies.

IN8bio is a New York-based clinical-stage biopharmaceutical company developing genetically modified gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for solid and hematologic malignancies. Lead programs include INB-100 (donor-derived γδ T cells for leukemia patients undergoing haploidentical transplant), INB-200 and INB-400 (autologous γδ T cells for glioblastoma), and INB-619, a CD19-targeting γδ T cell engager advancing into IND-enabling studies. The company reported $18.0M in cash at June 30, 2026. Co-founded in 2016 by CEO William Ho and scientific founder Dr. Lawrence Lamb.

Kopra Bio is a UCSF spinout and Y Combinator-backed biotech developing viral immunotherapies for cancer. Its proprietary InViTE (In Vivo Tumor Editing) platform uses genetically engineered viruses designed to selectively infect and destroy tumor cells, starting with glioblastoma.

Lisata Therapeutics is a Basking Ridge, New Jersey-based clinical-stage pharmaceutical company developing certepetide (formerly LSTA1 / CEND-1), a cyclic peptide tumor-penetration enhancer designed to improve intratumoral drug delivery of co-administered anti-cancer therapies. Certepetide is in active clinical development across multiple solid-tumor indications including pancreatic, gastric, cholangiocarcinoma, and glioblastoma, with a Phase IIa double-blind placebo-controlled GBM trial (Protocol LSTA1-GBM-2A) gating a contingent value right in the company's pending merger with Kuva Labs. On March 6, 2026 Lisata entered into a definitive agreement to be acquired by Kuva Labs for $4.00 per share in cash plus a non-tradeable CVR worth up to $3.00 per share (total potential consideration $7.00 per share subject to clinical and regulatory milestones). The merger outside date was extended from July 17, 2026 to July 21, 2026, with closing expected in Q3 2026 subject to financing and trial milestones.

MediciNova is a biopharmaceutical company developing small-molecule therapeutics licensed from Japanese originators for serious diseases with unmet medical need, and is dual-listed on Nasdaq and the Tokyo Stock Exchange. Its lead compound MN-166 (ibudilast) is an oral anti-inflammatory and neuroprotective agent in clinical development for amyotrophic lateral sclerosis (the Phase 2b/3 COMBAT-ALS registration trial enrolled 234 patients, with top-line data expected by year-end 2026), progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma and prevention of acute respiratory distress syndrome; an expanded-access program in ALS is supported by a $22 million NIH grant. The second compound, MN-001 (tipelukast), is an orally bioavailable small molecule in development for fibrotic and metabolic disorders including nonalcoholic fatty liver disease and hypertriglyceridemia. Management has framed 2026 as a data-driven year led by readouts from these two programs rather than by financing.

NeOnc Technologies Holdings is a clinical-stage biopharmaceutical company focused on treatments for intracranial malignancies. Its lead candidate NEO100, a purified form of perillyl alcohol delivered intranasally, is in Phase 2a development for recurrent IDH1-mutant high-grade glioma, with topline data expected in August 2026; NEO212, a covalent conjugate of temozolomide and perillyl alcohol, is in Phase 1/2 development for primary and secondary brain cancers including meningioma and glioblastoma. The company was founded by neurosurgeon-scientist Thomas C. Chen and is headquartered in Calabasas, California.

Radiopharm Theranostics is a clinical-stage radiopharmaceutical company developing paired diagnostic imaging and therapeutic candidates across several validated oncology targets, spanning peptides, small molecules and monoclonal antibodies radiolabelled with medical isotopes. Its pipeline pairs imaging agents such as 18F-RAD101 for recurrent brain metastases and Ga-68-RAD301 for pancreatic ductal adenocarcinoma with therapeutic assets including 177Lu-RAD202 in HER2-positive solid tumours and the B7-H3-targeted 177Lu-Betabart (RV-01) developed through a joint venture with MD Anderson Cancer Center. The company, which trades on both the ASX and Nasdaq, has a strategic agreement with Lantheus Holdings and isotope supply arrangements covering Lutetium-177 and Terbium-161.